JUNS

MKT CAP:$14M

Jupiter Neurosciences, Inc.

Market Cap

$14M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.39-$0.62 (-61.83%)

Apr 23, 2026

Company Details

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for t...

CEO

Christer Rosen

IPO Date

Jan 18, 2022

Website

www.jupiterorphan.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$8M

EPS (Diluted)

-$0.24

Free Cash Flow

-$7M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q3 2025

Nov 14, 2025

$0EPS -$0.07

Q2 2025

Aug 18, 2025

$0EPS -$0.07

Q1 2025

May 15, 2025

$0EPS -$0.05

FY 2024

Mar 28, 2025

$0EPS -$0.08

Q4 2024

Mar 28, 2025

$0EPS -$0.05

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 20	$1M	$1M	-$460.7K
Q1 21	$373.8K	$373.8K	-$228.8K
Q2 21	$264.3K	$264.3K	-$867.3K
Q3 21	$0	$0	-$1M
Q4 21	$0	$0	-$2M
Q1 23	$0	$0	-$1M
Q2 23	$0	$0	-$833.9K
Q3 23	$0	$0	-$1M
Q4 23	$0	$0	-$535.6K
Q1 24	$0	$0	-$570.7K
Q2 24	$0	$0	-$557.1K
Q3 24	$0	$0	-$493.5K
Q4 24	$0	$0	-$1M
Q1 25	$0	$0	-$2M
Q2 25	$0	$0	-$2M
Q3 25	$0	$0	-$2M

Valuation

Quarter	P/S	P/E
Q4 20	—	—
Q1 21	—	—
Q2 21	139.1x	—
Q3 21	139.1x	—
Q4 21	362.7x	—
Q1 23	875.7x	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 20	$158.4K	$158.4K
Q1 21	$39.4K	$39.4K
Q2 21	-$79.2K	-$79.2K
Q3 21	-$550.9K	-$550.9K
Q4 21	-$1M	-$1M
Q1 23	-$98.7K	-$98.7K
Q2 23	-$58.0K	-$58.0K
Q3 23	-$163.2K	-$163.2K
Q4 23	-$161.1K	-$161.1K
Q1 24	-$65.2K	-$65.2K
Q2 24	-$107.5K	-$107.5K
Q3 24	-$42.6K	-$42.6K
Q4 24	-$4M	-$4M
Q1 25	-$1M	-$1M
Q2 25	-$828.2K	-$828.2K
Q3 25	-$1M	-$1M

Capital Expenditures

Quarter	CapEx
Q4 20	$0
Q1 21	$0
Q2 21	$0
Q3 21	$0
Q4 21	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$5
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 21	—	+57.8%
Q4 21	-100.0%	+13.5%
Q1 23	-100.0%	+73.8%
Q2 23	-100.0%	-26.3%
Q3 23	—	+28.3%
Q4 23	—	-68.2%
Q1 24	—	-45.5%
Q2 24	—	-33.2%
Q3 24	—	-65.8%
Q4 24	—	+172.3%
Q1 25	—	+169.5%
Q2 25	—	+306.6%
Q3 25	—	+365.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 20	$113.0K	11.0%
Q1 21	$150.5K	40.3%
Q2 21	$347.7K	131.6%
Q3 21	$369.0K	—
Q4 21	$435.2K	—
Q1 23	$381.5K	—
Q2 23	$350.9K	—
Q3 23	$253.0K	—
Q4 23	$213.2K	—
Q1 24	$355.3K	—
Q2 24	$277.0K	—
Q3 24	$195.1K	—
Q4 24	$1M	—
Q1 25	$421.5K	—
Q2 25	$462.5K	—
Q3 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 20	$879.9K	$606.1K	—
Q1 21	$283.0K	$319.6K	—
Q2 21	$494.5K	$637.1K	—
Q3 21	$298.0K	—	$826.2K
Q4 21	$372.2K	—	$1M
Q1 23	$267.4K	—	$780.1K
Q2 23	$203.2K	$630.7K	—
Q3 23	$239.5K	$1M	—
Q4 23	$244.7K	$290.9K	—
Q1 24	$98.7K	$472.0K	—
Q2 24	$101.1K	$456.0K	—
Q3 24	$91.9K	$401.6K	—
Q4 24	$201.0K	$1M	—
Q1 25	$466.7K	$1M	—
Q2 25	$759.4K	$2M	—
Q3 25	$816.7K	—	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 20	$208.0K	$0	$208.0K
Q2 21	$735.7K	$0	$735.7K
Q3 21	$1M	$0	$1M
Q4 21	$330.6K	$0	$330.6K
Q1 22	$126.4K	$0	$126.4K
Q2 22	$598.5K	$0	$598.5K
Q4 23	$28.5K	$0	$28.5K
Q1 24	$8.3K	$0	$8.3K
Q2 24	$14.9K	$0	$14.9K
Q3 24	$253	$0	$253
Q4 24	$4M	$0	$4M
Q1 25	$3M	$0	$3M
Q2 25	$2M	$0	$2M
Q3 25	$723.8K	$0	$723.8K
Q4 25	$4M	$0	$4M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 20	9M	+1.6%	—
Q1 21	9M	0.0%	—
Q2 21	9M	+6.9%	—
Q3 21	9M	-7.9%	0.0%
Q4 21	9M	+1.6%	0.0%
Q1 23	39M	+338.0%	+338.0%
Q2 23	33M	-15.4%	+246.6%
Q3 23	26M	-19.7%	+202.1%
Q4 23	30M	+12.3%	+233.9%
Q1 24	33M	+10.9%	-15.4%
Q2 24	33M	0.0%	0.0%
Q3 24	31M	-5.5%	+17.7%
Q4 24	29M	-7.3%	-2.9%
Q1 25	33M	+15.0%	+0.7%
Q2 25	33M	+0.2%	+0.9%
Q3 25	34M	+2.6%	+9.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 20	—	—
Q1 21	—	—
Q2 21	—	—
Q3 21	—	—
Q4 21	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	$0	50K
Q1 25	$0	50K
Q2 25	$0	50K
Q3 25	$0	50K

Revenue / Employee